b'AML - FLT3 ITD MRD AssayClinical InformationMinimal residual disease (MRD) detection in patientsThe treatment of AML has become a paradigm for with leukemia has proven to be useful in the clinicalprecision medicine. This MRD assay is at least two orders management of disease and can facilitate the developmentof magnitude more sensitive than other commercially of new therapies. Mutations in the fms-like tyrosine kinaseavailable FLT3 assays. It detects the persistence of a driver 3 (FLT3) gene are the most prevalent mutations found inmutation, FLT3 ITD, in patients with no overt evidence acute myeloid leukemia (AML) 1and are characterized byof disease, allowing clinicians to identify those patients an aggressive phenotype with a high prevalence of relapse.that can benefit from continuation or modification of Internal tandem duplication (ITD) mutations within thetreatment. 3juxtamembrane domain are the most common mutations of FLT3. 2The development of a sensitive and specificMRD detection by Next-Generation Sequencing has assay for FLT3 ITD mutations represents a significantdemonstrated utility in predicting clinical outcomes advancement in guiding treatment decisions. and in generating clinically actionable results, allowing LabPMMs FLT3 ITD MRD test is an NGS-based, targeted,early intervention, confirmation of disease status prior to deep-sequencing assay that detects ITDs ranging from 3transplant, and increased confidence in remission status.bp to over 200 bp in size. Once a specific ITD (length and sequence) has been identified in a primary sample, it can easily be tracked in subsequent samples at a sensitivityof 5x10 -5 , provided sufficient DNA quantity is tested.References1.The Cancer Genome Atlas Research Network (2013) Genomic and Epigenomic Landscapes of Adult De Novo Acute MyeloidLeukemia. N Engl J Med. 368: 20592074.2.Konig H. et al. (2015) Targeting FLT3 to treat leukemia. Expert Opin Ther Targets 19:37-54.3.Levis, M. J. et al (2018) A next-generation sequencingbased assay for minimal residual disease assessment in AML patientswith FLT3-ITD mutations. Blood Advances, 2: 825-83136'